No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.
Fiche publication
Date publication
avril 2024
Journal
Diabetes & metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence, Pr PETIT Jean-Michel, Pr VERGES Bruno, Dr PAIS DE BARROS Jean-Paul
Tous les auteurs :
Duvillard L, de Barros JP, Rouland A, Simoneau I, Denimal D, Bouillet B, Petit JM, Vergès B
Lien Pubmed
Résumé
The catabolism of high density lipoprotein (HDL) apolipoprotein AI (apoAI) is accelerated in patients with type 2 diabetes (T2D), related to hypertriglyceridemia, insulin resistance and low plasma adiponectin levels. Since liraglutide is likely to partly correct these abnormalities, we hypothesized that it might have a beneficial effect on HDL apoAI kinetics in patients with T2D.
Mots clés
Apolipoprotein AI, High density lipoprotein, Kinetics, liraglutide, Type 2 diabetes
Référence
Diabetes Metab. 2024 04 21;:101535